Due to the COVID-19 pandemic, and the start of Brexit, when the U.K. left the European Union (EU), many transport options were highly impacted. These circumstances caused the shipment to be offloaded multiple times by the airline. Based on the criticality of this shipment, an alternative transport solution was required.
Marken's goal was to ensure on-time release and delivery of an autologous CAR-T Cell Treatment therapy to an investigator site in Spain. This case study presents the outcome.